The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges
Publication
, Journal Article
Oduah, EI; Lee, CS; Seetharamu, N
Published in: Journal of Thoracic Disease
June 1, 2022
Duke Scholars
Published In
Journal of Thoracic Disease
DOI
EISSN
2077-6624
ISSN
2072-1439
Publication Date
June 1, 2022
Volume
14
Issue
6
Start / End Page
1766 / 1771
Related Subject Headings
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Oduah, E. I., Lee, C. S., & Seetharamu, N. (2022). The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges. Journal of Thoracic Disease, 14(6), 1766–1771. https://doi.org/10.21037/jtd-22-432
Oduah, E. I., C. S. Lee, and N. Seetharamu. “The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges.” Journal of Thoracic Disease 14, no. 6 (June 1, 2022): 1766–71. https://doi.org/10.21037/jtd-22-432.
Oduah EI, Lee CS, Seetharamu N. The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges. Journal of Thoracic Disease. 2022 Jun 1;14(6):1766–71.
Oduah, E. I., et al. “The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges.” Journal of Thoracic Disease, vol. 14, no. 6, June 2022, pp. 1766–71. Scopus, doi:10.21037/jtd-22-432.
Oduah EI, Lee CS, Seetharamu N. The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges. Journal of Thoracic Disease. 2022 Jun 1;14(6):1766–1771.
Published In
Journal of Thoracic Disease
DOI
EISSN
2077-6624
ISSN
2072-1439
Publication Date
June 1, 2022
Volume
14
Issue
6
Start / End Page
1766 / 1771
Related Subject Headings
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences